03 Jul 2026

CRC Research Update — July 03, 2026

Creator: The CRC Digest
Published: 2026-07-03T21:28:44Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

KRYSTAL-10 trial: Adagrasib plus cetuximab does not outperform chemotherapy in KRAS G12C-mutated metastatic CRC
Phase III trial results presented at ESMO GI 2026 show that the combination of adagrasib (a KRAS G12C inhibitor) and cetuximab failed to demonstrate superiority over standard chemotherapy in patients with KRAS G12C-mutated metastatic colorectal cancer. (ESMO Daily Reporter)
Screening age lowered to 45 for average-risk patients as early-onset CRC rises
Guidelines now recommend screening begin at age 45 years (formerly 50 years) for average-risk patients, with high-risk patients starting at age 40 or earlier, in response to increasing rates of early-onset colorectal cancer among those under 55. (Gastroenterology Nursing)
Young adults with CRC face diagnostic delays, psychological distress, and fertility concerns
A study evaluated patients aged 15-39 years diagnosed with colorectal cancer between 2012 and 2025 using medical records, nursing documentation, multidisciplinary reports, and institutional assessment, finding that young adults often experience diagnostic delays, psychological distress, fertility-related concerns, and limited access to social support. (Journal of Adolescent and Young Adult Oncology)
Mismatch repair-deficient CRC with bowel obstruction shows excellent response to immunotherapy
A case series reports that patients with mismatch repair-deficient (dMMR) colorectal cancer presenting with bowel obstruction achieved excellent responses to immunotherapy. (Annals of Coloproctology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Long-term survival outcomes in young-onset rectal cancer patients
A retrospective study from a Norwegian university hospital (2014-2024) compared outcomes between patients under 50 and older age groups undergoing curative-intent rectal cancer resection, finding that young-onset rectal cancer is often diagnosed at advanced stages. (International Journal of Colorectal Disease)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Dual PD-1/PD-L1 blockade via siRNA delivery shows promise in MSS colorectal cancer
Preclinical research reports a peptide coacervate platform that delivers siRNA to silence both PD-1 in T-cells and PD-L1 in tumor cells, potentially enhancing immunotherapy in microsatellite-stable CRC, which typically shows limited response to checkpoint blockade. (Biomaterials)

Stay informed and keep advocating for your care.

CRC Research Update

Subscribe to The CRC Digest